SH-26 是一种 PHD1 PROTAC 降解剂,在 MDA-MB-231、HepG2 和 HEK-293T 细胞中对 PHD1 的 DC50 值分别为 1.06 μM、4.16 μM 和 4.91 μM,它可招募 CRBN 并通过泛素-蛋白酶体系统诱导 PHD1 降解,还能减轻 APAP (MS-H20928) 引发的活性氧 (ROS) 蓄积、线粒体功能障碍及 NLRP3 炎症小体激活,可用于急性肝损伤相关研究(粉色:HIF/HIF Prolyl-Hydroxylase 配体 (MS-H38708);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。
SH-26
产品编号: MS-T20174 分子式: C38H41N9O8 分子量: 751.79
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SH-26 是一种 PHD1 PROTAC 降解剂,在 MDA-MB-231、HepG2 和 HEK-293T 细胞中对 PHD1 的 DC50 值分别为 1.06 μM、4.16 μM 和 4.91 μM,它可招募 CRBN 并通过泛素-蛋白酶体系统诱导 PHD1 降解,还能减轻 APAP (MS-H20928) 引发的活性氧 (ROS) 蓄积、线粒体功能障碍及 NLRP3 炎症小体激活,可用于急性肝损伤相关研究(粉色:HIF/HIF Prolyl-Hydroxylase 配体 (MS-H38708);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。

生物实验数据

生物活性 SH-26 is a PHD1 PROTAC degrader with DC50 values of 1.06 μM, 4.16 μM, and 4.91 μM for PHD1 in MDA-MB-231, HepG2, and HEK-293T cells, respectively; it recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system, alleviates APAP (MS-H20928)-induced reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation, and can be used for research related to acute liver injury (pink: HIF/HIF Prolyl-Hydroxylase ligand (MS-H38708); blue: Cereblon ligand (MS-Q68284); black: linker).
IC50 & Target

NLRP3 inflammasome

 

PHD1

 

体外研究
(In Vitro)

SH-26 (Compound 26) (0.25-10 μM;2-72 小时) 可在 MDA-MB-231 细胞中诱导 PHD1 呈浓度和时间依赖性降解,其 48 小时时的 DC50 为 1.06 μM,Dmax 为 77.5%。
SH-26 (0.25-50 μM;48 小时) 以浓度依赖的方式诱导 HepG2 细胞中 PHD1 降解,其 DC50 为 4.16 μM。
SH-26 (0-50 μM;48 小时) 可在 HEK-293T 细胞中诱导浓度依赖性的 PHD1 降解,其 DC50 为 4.91 μM。
SH-26 (2-25 μM;48 小时) 以依赖泛素-蛋白酶体系统的方式介导 MDA-MB-231、HepG2 和 HEK-293T 细胞中 PHD1 的降解,该过程同时需要 PHD1 靶点结合和 CRBN 招募。
SH-26 (1-25 μM;预处理 4 小时) 在常氧条件下可降解 APAP 诱导损伤的 AML12 肝细胞中的 PHD1 和 PHD2 (但不降解 PHD3),并稳定 HIF-1α。
SH-26 (1-25 μM;预处理 4 小时) 在缺氧条件下对 APAP 处理的 AML12 肝细胞表现出浓度依赖性的 PHD1 降解增强作用 (DC50 = 0.13 μM),并可稳定 HIF-1α。
SH-26 (1-50 μM;预处理 4 小时) 可呈浓度依赖性保护 AML12 肝细胞免受 APAP 诱导的损伤,且无固有细胞毒性。
SH-26 (1-25 μM;预处理 4 小时) 可恢复 APAP 处理的 AML12 肝细胞中 HIF-1α 靶基因 BNIP3 和 SLC2A1 的表达,不影响 PHD1 的 mRNA 水平,并抑制 IL-1β 的 mRNA 水平。
SH-26 (1-50 μM;预处理 4 小时) 可呈剂量依赖性降解 PHD1 并抑制 APAP 处理的 AML12 肝细胞中 IL-1β 的蛋白水平。
SH-26 (1 μM;24 小时) 可降解 PHD1,并在 LPS (MS-X54539)+IFN-γ 刺激的 THP-1 来源 M1 巨噬细胞中下调促炎介质 IL-1β、IL-6 和 TNF-α。
SH-26 (1-25 μM;4 小时预处理) 可呈剂量依赖性地降低 APAP 刺激的 AML12 肝细胞中线粒体活性氧的积累。

Western Blot Analysis

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 2 h; 4 h; 8 h; 12 h; 24 h; 48 h; 72 h
Result: Induced 67% PHD1 degradation at 24 h, 70% at 48 h, and 80% at 72 h at 2 μM.
Induced concentration-dependent PHD1 degradation with a DC50 of 1.06 μM and a maximum degradation (Dmax) of 77.5%.
Caused significant degradation within 4 h, with maximal depletion achieved by 72 h.
Showed no hook effect at concentrations up to 10 μM.

Western Blot Analysis

Cell Line: HepG2 hepatoma cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 48 h
Result: Induced concentration-dependent PHD1 degradation with a DC50 of 4.16 μM.

Western Blot Analysis

Cell Line: HEK-293T embryonic kidney cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 48 h
Result: Induced concentration-dependent PHD1 degradation with a DC50 of 4.91 μM.

Western Blot Analysis

Cell Line: MDA-MB-231, HepG2, and HEK-293T cells
Concentration: 2 μM; 25 μM
Incubation Time: 48 h
Result: Had its PHD1-degrading activity blocked in all three cell lines when cotreated with MG132, MLN4924, Takeda-54, or SH-28.

Western Blot Analysis

Cell Line: AML12 hepatocytes
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Degraded PHD1 in a concentration-dependent manner.
Degraded PHD2 with a DC50 of 1.83 μM and a Dmax of 71.8%.
Did not degrade PHD3.
Stabilized HIF-1α in a concentration-dependent manner.

Western Blot Analysis

Cell Line: AML12 hepatocytes
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Exhibited enhanced PHD1 degradation under hypoxia with a DC50 of 0.13 μM.
Stabilized HIF-1α in a concentration-dependent manner.

Cell Viability Assay

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
Incubation Time: 4 h pretreatment
Result: Attenuated APAP-induced hepatotoxicity in a concentration-dependent manner.
Exhibited no inherent cytotoxicity at tested concentrations.

Real Time qPCR

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 5 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Restored BNIP3 mRNA to baseline levels and significantly upregulated SLC2A1 mRNA at 10 μM.
Did not alter PHD1 mRNA levels.
Dose-dependently suppressed IL-1β mRNA levels.

Western Blot Analysis

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
Incubation Time: 4 h pretreatment
Result: Dose-dependently degraded PHD1.
Dose-dependently suppressed IL-1β protein levels.
体内研究
(In Vivo)

SH-26 (Compound 26) (10-30 mg/kg;腹腔注射;单次给药) 对 APAP 诱导的急性肝损伤具有显著的保肝作用。

Animal Model: C57BL/6 (male, 8 weeks old, APAP-induced acute liver injury)
Dosage: 10 mg/kg; 30 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CRE), and blood urea nitrogen (BUN) at 30 mg/kg.
Markedly attenuated APAP-induced hepatic damage, confirmed by histopathological analysis and necrotic area quantification at 10 mg/kg and 30 mg/kg.
Effectively reversed APAP-induced upregulation of PHD1 protein expression and induced robust PHD1 degradation in liver tissue at 10 mg/kg and 30 mg/kg.
Significantly reduced the upregulation of inflammasome components (NLRP3, GSDMD, cleaved caspase 1, cleaved IL-1β) at 10 mg/kg and 30 mg/kg.
Attenuated pro-apoptotic signals (increased BAX/BCL2 ratio, elevated cleaved caspase 3 levels) at 10 mg/kg and 30 mg/kg.
Significantly reduced liver tissue expression of immune cell markers LY6G, F4/80, CD31, and CD3 at 10 mg/kg and 30 mg/kg.

化学信息

分子量 751.79
分子式 C38H41N9O8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础